BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36146944)

  • 1. Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
    Choueiri TK; Porta C; Suárez C; Hainsworth J; Voog E; Duran I; Reeves J; Czaykowski P; Castellano D; Chen J; Sedarati F; Powles T
    Oncologist; 2022 Dec; 27(12):1048-1057. PubMed ID: 36146944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
    Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
    Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
    McGregor BA; Xie W; Adib E; Stadler WM; Zakharia Y; Alva A; Michaelson MD; Gupta S; Lam ET; Farah S; Nassar AH; Wei XX; Kilbridge KL; Harshman L; Signoretti S; Sholl L; Kwiatkowski DJ; McKay RR; Choueiri TK
    JCO Precis Oncol; 2022 Feb; 6():e2100448. PubMed ID: 35171658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
    Han SN; Oza A; Colombo N; Oaknin A; Raspagliesi F; Wenham RM; Braicu EI; Jewell A; Makker V; Krell J; Alía EMG; Baurain JF; Su Z; Neuwirth R; Vincent S; Sedarati F; Faller DV; Scambia G
    Gynecol Oncol; 2023 Nov; 178():110-118. PubMed ID: 37839313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
    Motzer RJ; Hutson TE; Glen H; Michaelson MD; Molina A; Eisen T; Jassem J; Zolnierek J; Maroto JP; Mellado B; Melichar B; Tomasek J; Kremer A; Kim HJ; Wood K; Dutcus C; Larkin J
    Lancet Oncol; 2015 Nov; 16(15):1473-1482. PubMed ID: 26482279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
    Rajdev L; Lee JW; Libutti SK; Benson AB; Fisher GA; Kunz PL; Hendifar AE; Catalano P; O'Dwyer PJ
    Invest New Drugs; 2022 Dec; 40(6):1306-1314. PubMed ID: 36264382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.
    García-Sáenz JÁ; Martínez-Jáñez N; Cubedo R; Jerez Y; Lahuerta A; González-Santiago S; Ferrer N; Ramos M; Alonso-Romero JL; Antón A; Carrasco E; Chen J; Neuwirth R; Galinsky K; Vincent S; Leonard EJ; Slamon D
    Clin Cancer Res; 2022 Mar; 28(6):1107-1116. PubMed ID: 34980598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors.
    Starks DC; Rojas-Espaillat L; Meissner T; Williams CB
    Gynecol Oncol; 2022 Sep; 166(3):403-409. PubMed ID: 35843739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
    Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
    Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
    Powles T; Lackner MR; Oudard S; Escudier B; Ralph C; Brown JE; Hawkins RE; Castellano D; Rini BI; Staehler MD; Ravaud A; Lin W; O'Keeffe B; Wang Y; Lu S; Spoerke JM; Huw LY; Byrtek M; Zhu R; Ware JA; Motzer RJ
    J Clin Oncol; 2016 May; 34(14):1660-8. PubMed ID: 26951309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
    Wood A; George S; Adra N; Chintala S; Damayanti N; Pili R
    Invest New Drugs; 2020 Aug; 38(4):1108-1116. PubMed ID: 31654285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.
    Pal SK; Puente J; Heng DYC; Glen H; Koralewski P; Stroyakovskiy D; Alekseev B; Parnis F; Castellano D; Ciuleanu T; Lee JL; Sunela K; O'Hara K; Binder TA; Peng L; Smith AD; Rha SY
    Eur Urol; 2022 Sep; 82(3):283-292. PubMed ID: 35210132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
    Hutson TE; Michaelson MD; Kuzel TM; Agarwal N; Molina AM; Hsieh JJ; Vaishampayan UN; Xie R; Bapat U; Ye W; Jain RK; Fishman MN
    Eur Urol; 2021 Aug; 80(2):162-170. PubMed ID: 33867192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
    Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.
    Staehler M; Stöckle M; Christoph DC; Stenzl A; Potthoff K; Grimm MO; Klein D; Harde J; Brüning F; Goebell PJ; Augustin M; Roos F; Benz-Rüd I; Marschner N; Grünwald V
    Int J Cancer; 2021 Apr; 148(7):1685-1694. PubMed ID: 33070307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
    Lim B; Potter DA; Salkeni MA; Silverman P; Haddad TC; Forget F; Awada A; Canon JL; Danso M; Lortholary A; Bourgeois H; Tan-Chiu E; Vincent S; Bahamon B; Galinsky KJ; Patel C; Neuwirth R; Leonard EJ; Diamond JR
    Clin Cancer Res; 2021 Jun; 27(12):3329-3338. PubMed ID: 33820779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
    Voss MH; Gordon MS; Mita M; Rini B; Makker V; Macarulla T; Smith DC; Cervantes A; Puzanov I; Pili R; Wang D; Jalal S; Pant S; Patel MR; Neuwirth RL; Enke A; Shou Y; Sedarati F; Faller DV; Burris HA
    Br J Cancer; 2020 Nov; 123(11):1590-1598. PubMed ID: 32913286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.